Table 1.
Patient characteristics of stage IV NSCLC patients with 1L pembrolizumab or 2L nivolumab.
| Pembrolizumab 1st line | Nivolumab 2nd line | |||
|---|---|---|---|---|
| Real-world | RCT5 | Real-world | RCT2 | |
| Subjects | 83 | 154 | 141 | 292 |
| Male | 45 (54%) | 92 (60%) | 74 (53%) | 151 (52%) |
| Age (median (range)) | 66.0 (35–84) | 64.5 (33–90) | 64.0 (44–80) | 61.0 (37–84) |
| ECOG PS | ||||
| 0 | 30 (36%) | 54 (35%) | 44 (31%) | 84 (29%) |
| 1 | 50 (60%) | 99 (64%) | 90 (64%) | 208 (71%) |
| 2 | 3 (4%) | 1 (1%) | 7 (5%) | – |
| Histology | ||||
| Squamous | 11 (13) | 29 (19%) | – | – |
| Non-squamous | 72 (87) | 125 (81%) | 141 (100%) | 292 (100.0) |
| PD-L1 expression | ||||
| < 1% | – | – | 33 (23%) | 108 (37%) |
| 1–49% | – | – | 29 (21%) | 123* (42%) |
| ≥ 50% | 83 (100%) | 154 (100%) | 10 (7%) | |
| Unknown*** | – | – | 69 (49%) | 61 (21%) |
| CNS metastases | 16 (19%) | 18 (12%) | 25 (18%) | 34 (12%) |
| Subsequent systemic therapy | 14 (17%) | 56 (36%)** | 40 (28%) | 123 (42%) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; CNS, central nervous system; RCT, randomized clinical trial.
*PD-L1 expression of ≥ 1%.
**Including surgery and radiation therapy.
***Not performed in real-world; not quantifiable from RCT2.